Background. Advanced pancreatic adenocarcinoma is a rapidly fatal disease for which an active chemotherapy regimen is sought. Here we report the outcome of a phase II trial to assess the toxicity and efficacy of a combination of 5-fluorouracil (5-FU), leucovorin and cisplatin (CDDP).
Introduction
Adenocarcinoma of the pancreas is a virulent malignancy with a short survival. Despite major advances in surgical procedures, radiation and chemotherapy, the prognosis of this cancer remains a dismal less-than-5% survival at 5 years [1, 2] . Traditionally, surgery has been considered the only curative modality for this disease [3] ; at the time of diagnosis the majority of patient have locally advanced or metastatic inoperable tumors.
The aim of palliative chemotherapy in pancreatic cancer is to improve symptoms and survival with low toxicity, and 5-fluorouracil (5-FU) is the most widely studied and used agent [4] . In general, according to the prospective randomized trials, fewer than 20% of patients respond to 5-FU [1, 2] . Several combination regimens have been tested. Of those assessed in randomized trials, the median survival ranged from 2 to 6.5 months and was not significantly better than that of supportive care alone [1, 2, 5, 6] . Four randomized studies have compared chemotherapy (without CDDP) vs. supportive care, with only 2 of them [7, 8] demonstrating benefit in terms of overal survival in patients receiving a combination chemotherapeutic regimen. These results, however, remain open to discussion [5] [6] [7] [8] .
In vitro and in vivo studies have provided evidence that the cytotoxic effects of 5-FU are enhanced by leucovorin [9, 10] and cisplatin [11] [12] [13] . We report herein our observations in a prospective phase II study administering the combination of leucovorin, 5-FU, and CDDP to patients with locally advanced and/or metastatic, previously untreated, pancreatic adenocarcinoma.
Materials and methods

Patient population
This trial was conducted in a single institution between January 1987 and January 1995. Fifty-two patients with histologically-or cytologically-proven non-resectable or metastatic adenocarcinoma of the pancreas were enrolled in this study. Histological or cytological diagnoses were obtained by surgical biopsy or by fine-needle aspiration biopsy under CT scan or ultra-sound guidance using a two-needle coaxial technique. Neuroendocrine and acinar pancreatic carcinomas were excluded, as were distal common bile duct and ampular region carcinomas. Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) grade of 0 to 3, and those with prior radiotherapy or chemotherapy were not enrolled. Prior surgical digestive and biliary bypass procedures were accepted. The median time between histologic diagnosis and start of chemotherapy was 6 weeks (range: 2 weeks to 5 months).
Patients were required to have at least one bidimensional lesion measurable on a CT scan and abdominal ultrasonography, and a leukocyte count >4 x lO'/l, a neutrophil count > 1.5 x 10 9 /l, a platelet count > 100 x 10'/l and normal renal function (serum creatinine level<1.5 mg/dl). Abnormal bilirubin level with jaundice was not an exclusion criteria. Active heart disease was a contra-indication to patient inclusion. Informed consent was obtained from each patient
Drug therapy
Chemotherapy consisted of a 5-day course of leucovorin given at 200 mg/m 2 /d by an intravenous (i.v.) bolus injection followed by infusion of 5-FU (375 mg/mVd in 1 1 of saline over 2 hours), followed by infusion of CDDP (15 mg/m 2 /d in 250 ml of saline over 1 hour). After CDDP administration, 1 1 of saline was infused over 2 hours. Cycles were repeated every 21 days. In the absence of gastrointestinal and hematologic toxicities, the daily dose of 5-FU was increased by 25 mg/m 2 /d at each subsequent cycle (the maximum daily dose was 550 mg/m 2 /d). Antiemetics were routinely prescribed and consisted of i.v. metoclopramide, granisetron or ondansetron. Careful dental hygiene, including the prophylatic use of antiseptic and antimycotic solutions, was recommended to prevent oral mucositis. Most of the patients had a permanent venous access device. If at the time of the ongoing course, the neutrophil count had not reached 1.5 x 10 9 /l and/or the platelet count 100 x 1O 9 /1, the treatment was delayed until the values reached normal level and the doses of 5-FU and CDDP were decreased by 25 mg/mVd and 5 mg/mVd, respectively. In instances of World Health Organization (WHO) grade HI-IV gastrointestinal toxicity, the 5-FU dose was reduced by 25% and in instances of WHO grade > I peripheral neuropathy, CDDP was definitively withdrawn from the therapeutic regimen.
Pretreatment and follow-up investigations
Baseline studies included physical examination, PS, complete blood count, biochemical profile, CA 19-9 (normal value <35 U/ml), and chest X-ray. Tumor size was determined by abdominal CT scan and ultrasonography as well as by other investigations as indicated. Complete blood cell count and serum creatinine level were determined on the first day of each cycle, and all baseline investigations, including tumor measurements and CA 19-9, were repeated every 3 cycles until progression of the disease was documented. Treatment was continued as long as patients had complete response (CR), partial response (PR) or stable disease (SD).
Treatment was discontinued when tumor progression or unacceptable toxic side effects occurred or the patient refused its continuation.
Definition of response
The response criteria used were those defined by the WHO. The patients who died of progressive disease (PD) before the first evaluation were considered treatment failures. When an increase in serum CA 19-9 levels was noted before therapy, a decline of more than 50% lasting for a period of more than 4 weeks was considered a biologic response for this tumor marker. Palliative effects, assessed by investigators at the beginning of each cycle, were considered positive when patients' PS improved, body weight increased of > 5% over their pretreatment weight, or their pain decreased, for more than 4 weeks. Pain was subjectively evaluated and we considered that pain was attenuated if analgesic consumption decreased.
Statistical methods
The study end points were survival, progression free survival, toxicity and symptomatic response. Confidence intervals (CI) for the overall response rate were computed using the normal approximation to the binominal. Survival was defined as the time, in months, from the initiation of chemotherapy and was calculated using the Kaplan-Meier method. Toxicity was reported using the WHO standard criteria.
Results
Fifty-two patients were enrolled in this trial and their characteristics are reported in Table 1 . A total of 334 cycles were administered to the 52 patients with a median of 6 cycles per patient (range: 1-19). Four patients were not assessed for response, but were evaluated for toxicity and survival studies. These 4 patients had undergone a Whipple resection or partial pancreatectomy; 2 of them had unmeasurable macroscopic residual disease, and 2 had microscopic residual disease. The survival durations of these 4 patients were, respectively, 12+, 14+, 23 and 25 months. Of the remaining 48 patients, 9 could be assessed for response at the pancreatic site (extended locoregional disease), 31 could be assessed for response at the metastatic sites and eight patients with metastatic disease died before the time of first evaluation and were considered to have PD. Their deaths were not attributable to toxic side effects.
Toxicity
Toxicity data of all of the patients are presented in Table 2 . Toxicity was assessed just before each cycle of chemotherapy. The most frequently encountered adverse reactions were nausea and vomiting. The incidence of this side effect has decreased since the systematic utilization of a serotonin antagonist was begun in 1990. Anemia was frequent (17% grade 3-4), and 15 patients required blood transfusions. Drug doses were lowered to counteract hematotoxicity in 6 patients (12%) and toxic gastrointestinal (oral mucositis and/or diarrhea) side effects in 6 patients (12%). Three patients (6%) were hospitalized for granulocytopenic fever. Six patients (12%) experienced grade 3-4 granulocytocypenia. Five patients (10%) had grade 3 thrombocytopenia without purpura or hemorrhage. The low incidence of toxicity (neutropenia, thrombocytopenia, mucositis and/or diarrhea) can be explained by the 2-hour infusion of 5-FU. Only grades 1-2 renal toxicities were observed (14%). Among the 19 patients who had received more than 6 cycles of therapy peripheral neurotoxicity was frequent, with 11 documented cases (21%) of grade 2 peripheral neuropathy that necessitated discontinuation of CDDP. Peripheral neuropathy always regressed after CDDP withdrawal.
Response
Of 48 evaluable patients, 10 achieved PR; no CRs were observed. The overall response rate was 21% (95% CI: 9.5%-32.5%). Seven PR were observed in patients with metastatic disease and 3 PR in patients with extended locoregional disease. In all of the 7 responding patients with metastatic disease, the sites of response were the liver metastasis; response in the pancreatic tumor was considered inevaluable in 4 patients, partial (PR) in two 
Survival
The overall median survival time (Figure 1 ) was 9.5 months (range: 1-44 months) for the population as a whole, 18 months for locally advanced disease and 5 months for metastatic disease; it was 20 months (range: 6-44 months) for patients with an objective response and 6 months (range: 1-29 months) for the nonresponding patients. The median time to progression for all patients was 4.5 months and 18 patients (34.6%) are alive at 1 year.
Biologic response and palliative effect
A biologic response (decline > 50% of CA 19-9 level) was observed in 52% of the patients (22/42). This response was seen in all of the radiologically-determined objective responders who had increased CA 19-9 levels before chemotherapy (8 cases) and, interestingly, it was noted in 12 of the 17 patients with SD and palliative effects. No biologic responses were seen in patients with PD at the time of the first evaluation. Palliative effects (improved PS, body weight gain > 5%, or lower pain) were seen in 27 of 52 patients (52%): best PS n a n o
The percentages of patients suffering from different grades of toxicity is indicated. The worst grade of toxicity observed was taken into consideration for each patient were recorded for 20/45 patients (44.5%); pain was attenuated in 27/44 patients (61%) with a concomitant decrease of analgesic consumption; 17/52 patients (33%) had weight gain of > 5% of their body weight.
Discussion
In patients with pancreatic carcinoma, several combination chemotherapeutic regimens have been tested. Using these, median survival has ranged from 2 to 6.5 months and has not been significantly better than that obtained with supportive care alone [5, 6] . Only 2 studies have found a survival advantage with chemotherapy [7, 8] . The median survival of patients with advanced pancreatic adenocarcinoma is usually less than 5 months, and even less than 3 months for patients with metastatic disease [2] . 5-FU is the chemotherapeutic agent most widely used in the treatment of patients with pancreatic cancer. A literature review that included 212 patients with carcinoma of the pancreas treated with 5-FU found an overall response rate of 28%, but most investigators consider this to be an erroneously high estimate of the response rate [4] . In prospective randomized trials, fewer than 20% of the patients responded to 5-FU, but the optimal dose and administration schedules of 5-FU
have not yet been defined [1, 5, 6] . Different administration protocols have not been extensively compared prospectively in patients with pancreatic cancer, nor has a dose-intensity analysis been performed.
However, attention has been focused on the biochemical modulation of 5-FU by leucovorin. Studies in patients with colorectal cancer, gastric cancer, and breast cancer have yielded encouraging results [10] .
Among 78 assessable patients with advanced adenocarcinoma of the pancreas reported in four studies, only a 9% objective response rate to 5-FU and leucovorin was observed [14] [15] [16] [17] . This combination has not been shown to be superior to 5-FU alone.
The results obtained with CDDP alone or combined with different agents in patients with pancreatic cancer are summarized in Table 3 [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . Response rates ranged from 0% to 39% and median survival from 3.5 to 14 months. Two studies reported the results of CDDP used as a single agent in patients with pancreatic carcinoma: Kantarjian et al. reported no PR in 14 patients and Wils et al. reported a 21% objective response rate in 33 patients [18, 19] . When CDDP was combined with 5-FU interesting palliative results were reported [20] [21] [22] [23] [24] [25] [26] [27] .
Tumor response is difficult to assess in a pancreatic tumor mass when no measurable metastatic disease exists, since an enlarged pancreas seen on a CT scan Rothman et al. [25] Gattani et al. [26] Nicolson et al. [27] Present study does not correspond to pancreatic cancer tissue only, but includes normal pancreatic tissue and secondary pancreatitis in addition to the tumor tissue. This inability to accurately measure the tumor response may explain some of the differences in response rates reported among trials using chemotherapy in a large number of patients with locoregional disease.
In this study, we obtained a 21% overall response rate in 48 assessable patients and a median response duration of 12.4 months (range: 3-25 months).
These data are even more interesting if we consider that 75% of our patients had metastatic disease and 52% had poor PS (grade 2 or 3). Three of the 10 objective responses obtained were observed in patients with only locoregional disease. The most striking results of our study are the 9.5-month median survival and the frequent palliative effects obtained. However, these results must be interpreted with caution when comparing them with other series, as this study was non-randomized and case selection can thus play a large role. It is also possible that the dismal historical survival of patients with pancreatic adenocarcinoma has been changed by early diagnosis, stent, antibiotics and, more generally, better supportive care. This is probably true for locally advanced tumors but not for metastatic disease. Our median survival duration of 18 months for patients with locally advanced disease (13/52 patients) may explain an overall median survival time of 9.5 months for the entire population of patients. Our results are similar to those of the Nicolson study, especially for patients with locally advanced disease in whom the median survival time was 14.6 months and the 1-year survival rate 53% [27] . Our toxic side effects were acceptable compared to those in previous literature concerning 5-FU bolus and high-dose folinic acid despite the addition of CDDP [28] . We suggest that the low rate of mucositis, diarrhea and leucopenia is related to the 2-hour infusion of 5-FU as opposed to bolus injection.
In conclusion, the 5-day regimen combining leucovorin, 5-FU and CDDP seems to be an effective palliative therapy for non-pretreated, advanced pancreatic cancer accompanied by acceptable toxicity. Further studies to evaluate the quality of life using a validated scale to more precisely define the palliative effect of chemotherapeutic regimens are required. A multicenter randomized trial comparing this therapeutic combination with supportive care has been initiated in France to further investigate its effect on survival.
